Cocoa (CC)

Dernières nouvelles pour Chemours (NYSE:CC) Stock

CHEMOURS CO/THE

Chemours

The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

The Chemours Co

COASTAL CAPITAL ACQSTN CP by Coastal Capital Acquisition Corp.

Coastal Capital Acquisition Corp

Crescent Capital BDC, Inc. - Common Stock

Crescent Capital BDC Inc

COLONIAL COAL INTL ORD by Colonial Coal International Corp

Colonial Coal International Corp

CARLOS CASADO SA S/ADR B by Carlos Casado S.A.

Carlos Casado SA

Coastal Financial Corporation - Common Stock

Coastal Financial Corp

CHINO COMML BANCORP (CA) by Chino Commercial Bancorp

Chino Commercial Bancorp

Capital City Bank Group Inc

CHINA CBM GROUP CO LTD by CHINA CBM GROUP CO LTD.

C4 Therapeutics Inc

CARLYLE COMMODITIES CORP by CARLYLE COMMODITIES CORP.

Carlyle Commodities Corp

CITY CHIC COLLECTIVE LTD by City Chic Collective Ltd.

City Chic Collective Ltd

CHINA CABLE & COMMUNS INC by China Cable & Communication, Inc.

China Cable and Communication Inc

CANCOM SE

Crona Corp

CCC Intelligent Solutions Holdings Inc. - Common Stock

CCC Intelligent Solutions Holdings Inc

Calamos Dynamic Convertible & Income Fund - Closed End Fund

Calamos Dynamic Convertible and Income Fund

Concordium - United States Dollar

CCL INDUS INC B CDA by CCL Industries Inc.

CCL Industries Inc

CAN DO COMPANY LTD TOKYO by Can Do Co., Ltd.

Can Do Co Ltd

Capital Clean Energy Carriers Corp. - Common Share

Capital Clean Energy Carriers Corp

CASCADERO COPPER CORP by Cascadero Copper Corp.

Cascadero Copper Corp

Calamos ETF Trust Calamos CEF Income & Arbitrage ETF

CARCLO ENGR PLC ORD by Carclo Engineering Plc

Carclo PLC

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International Inc

Coca-Cola Europacific Partners plc - Ordinary Shares

Coca-Cola Europacific Partners PLC

Cal-Comp Electronics (Thailand) PCL Units Non-Voting Depository Receipt

Cal-Comp Electronics (Thailand) PCL

Chase Corp. Com.

CCSB Financial Corp Com

CCF Holdings LLC

MUNCY COLUMBIA FNCL by Muncy Columbia Financial Corporation

Muncy Columbia Financial Corp

Cheche Group Inc. - Class A Ordinary Shares

Cheche Group Inc

CHINA CINDA ASSET MGMT CO by China Cinda Asset Management Co Ltd

China Cinda Asset Management Co Ltd

CREDIT CORP GROUP LTD by Credit Corp Group Ltd.

Credit Corp Group Ltd

China CGame Inc

C&C Group PLC

CHINA CLEAN ENERGY INC by China Clean Energy, Inc.

China Clean Energy Inc

COCA COLA HBC LTD ORD by COCA COLA HBC LTD

Coca-Cola HBC AG

COCA COLA HBC UNSP/ADR by Coca-Cola HBC AG

CAMBRIDGE CAP HLDGS INC by Cambridge Capital Holdings, Inc.

Cambridge Capital Holdings Inc

CENTRAL CHINA MGMT CO LTD by CENTRAL CHINA MGMT CO LTD.

Central China Management Co Ltd

CENTRAL CHNA NEW LIFE LTD by CENTRAL CHINA NEW LIFE LTD.

The Cannabist Company Holdings Inc

CAREER COLLEGE HLDG CO by Career College Holding Co., Inc .

Career College Holding Co Inc

Crown Castle Inc

Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028

Carlyle Credit Income Fund

Carlyle Credit Income Fund Shares of Beneficial Interest

Cohen Circle Acquisition Corp. I - Class A Ordinary Shares

Cohen Circle Acquisition Corp I

Cohen Circle Acquisition Corp. I - Warrant

Churchill Capital Corp IX - Ordinary Shares

Churchill Capital Corp IX

Cameco Corp

Crown Holdings Inc

Clicks Group Ltd

Carnival Corp

CareCloud Inc

CareCloud, Inc. - 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock

CareCloud Inc 11 % Cum Red Perp Pfd Registered Shs Series -A-

CC LAND HOLDINGS LTD ORD by CC Land Holdings Ltd.

C C Land Holdings Ltd

CCL INDUS INC CL (A) ORD by CCL Industries Inc.

CSI Compressco LP Com Unit

Chori Co Ltd

CABLECLIX (USA) INC by CableClix (USA), Inc.

CableClix (USA) Inc

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services Holdings Ltd

EA Series Trust CCM Global Equity ETF

CMC MARKETS PLC LON ORD by CMC Markets PLC London

CMC Markets PLC

CALLAHAN CONSOL MINES by Callahan Consolidated Mines, Inc.

COASTAL CAROLINA BANC by Coastal Carolina Bancshares Inc

Coastal Carolina Bancshares Inc

Kaizen Discovery Inc

CNB Financial Corp

CNB Financial Corporation - Depositary shares, each representing a 1/40th ownership interest in a share of 7.125% Series A Fixed- Rate Non-Cumulative Perpetual Preferred Stock

COCONALA INC by COCONALA INC.

ALPS/CoreCommodity Natural Resources ETF

Concentric AB

Clear Channel Outdoor Holdings, Inc. Common Stock

Clear Channel Outdoor Holdings Inc

CENTURY COBALT CORP by Century Cobalt Corp.

Century Cobalt Corp

Capcom Co Ltd

CHINA ST CONSTR INTL HLDG by China State Construction International Holdings, Ltd.

China State Construction International Holdings Ltd

Cogent Communications Holdings, Inc. - Common Stock

Cogent Communications Holdings Inc

COCA COLA BOTTLERS JAPAN by Coca-Cola Bottlers Japan Inc.

Coca-Cola Bottlers Japan Holdings Inc

COCA COLA BOTTLRS JPN ADR by Coca-Cola Bottlers Japan Inc.

Core Assets Corp

CANADIAN COPPER INC by CANADIAN COPPER INC.

Core Alternative ETF

CANACCORD GENUITY GRP INC by Canaccord Genuity Group, Inc.

Canaccord Genuity Group Inc

CHINA COAL ENGY CO H SHS by China Coal Energy Co., Ltd.

China Coal Energy Co Ltd

CHINA COAL ENGY CO ADR by China Coal Energy Co., Ltd.

SYN PROP E TECH GDR 144A by SYN Prop e Tech SA

SYN Prop E Tech SA

CAPITAL & COUNTIES ORD by Capital & Counties Properties PLC, London

Shaftesbury Capital PLC

SATO TECHNOLOGIES CORP by SATO TECHNOLOGIES CORP

SATO Technologies Corp

CoreCard Corp

CONCORDIA FINCL GRP LTD by Concordia Financial Group, Ltd.

Concordia Financial Group Ltd

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare Inc

GREEN RIVER GOLD CORP by Green River Gold Corp.

Green River Gold Corp

iShares U.S. ETF Trust iShares Commodity Curve Carry Strategy ETF

Century Communities Inc

<ul>
<li>Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).</li>
<li>The ‘782 patent, which issued on June 14, 2022, arises out of the same patent family as U.S. Patent No. 10,716,793 (the ‘793 patent) and claims the same general method of administering inhaled treprostinil to pulmonary hypertension patients. As disclosed in July 2022, the ‘793 patent was held to be invalid in a proceeding before the Patent Trial and Appeal Board (PTAB). The PTAB's decision was affirmed by the&nbsp;U.S. Court of Appeals for the Federal Circuit&nbsp;in&nbsp;December 2023. The United States Supreme Court&nbsp;rejected UTHR's petition for a writ of certiorari, thereby upholding PTAB's decision which found that all claims of the ‘793 patent are unpatentable due to prior art as final and not subject to further appeal.</li>
<li>UTHR is currently not seeking any injunction against the FDA to prevent final approval of the New Drug Application (NDA) for YUTREPIA. As previously announced, the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.</li>
</ul>

Biotech

News

Health Care

Legal

General

LQDA

UTHR

United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.walkerdunlop.com%2F&amp;esheet=54252815&amp;newsitemid=20250512455389&amp;lan=en-US&amp;anchor=Walker+%26amp%3B+Dunlop%2C+Inc.&amp;index=1&amp;md5=1495e66b29aae4d37b0eaffd41071612">Walker &amp; Dunlop, Inc.</a> is celebrating the ground breaking of Parkside 5, the fifth and final phase of the Parkside at Old Town development, a 99-unit community located on the former Cabrini-Green public housing site in Chicago's Near North Side.
&nbsp;
&nbsp;
Parkside 5 Groundbreaking. (Photo courtesy of Holsten Real Estate Development Corp.)
The Walker &amp; Dunlop affordable housing team, led by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.walkerdunlop.com%2Fabout%2Fpeople%2Fjen-erixon&amp;esheet=54252815&amp;newsitemid=20250512455389&amp;lan=en-US&amp;anchor=Jennifer+Erixon&amp;index=2&amp;md5=3497114b7444654b189ea95a93a6c8ae">Jennifer Erixon</a>, syndicated Low Income Housing Tax Credits (LIHTC) and Illinois Donation Tax Credits on behalf of the client, Holsten Real Estate Development Corporation. Walker &amp; Dunlop Affordable Equity syndicated the equity to JP Morgan, resulting in $22.6 million of equity to support the development. In addition to syndicating the credits, JP Morgan is also providing a construction loan for the project.
The funding will support the construction of a mix of market-rate and affordable units, with 37 of the units benefiting from a 20-year Section 8 Housing Assistance Payment (HAP) contract. These affordable units will be reserved for households earning 50% and 60% of the area median income (AMI) or less. "We are proud to support the continued revitalization of the Near North Side, helping to bring much-needed affordable housing options to the community while contributing to the broader transformation of the former Cabrini-Green site," said Jennifer Erixon, senior managing director of Affordable Equity Originations at Walker &amp; Dunlop. "Our partners at Holsten have allowed us to provide a valuable solution that meets our shared goals."
Parkside 5 will feature three 3-story walk-up buildings and an 8-story mid-rise structure with townhome units at its base. Planned amenities include a community room, fitness center, and onsite social services for residents. Additionally, a playground, and dog park, will be open to the community to position Parkside 5 as a vibrant, inclusive space for its residents and neighbors. The development will complement the existing phases of the Parkside at Old Town project, a key piece in the ongoing revitalization of the historic neighborhood.

Final Phase of Chicago's Cabrini-Green Revamp Breaks Ground With 99 New Homes, Backed by Walker & Dunlop

Canlan Ice Sports (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ICE#TSX">ICE</a>) reported quarterly earnings of $0.32 per share. This is unchanged from the same period last year. The company reported $27.98 million in sales this quarter. This is a 6.85 percent increase over sales of $26.19 million the same period last year.

Earnings

TSX:ICE

Canlan Ice Sports Q1 EPS $0.32, Same YoY, Sales $27.98M Up From $26.19M YoY

<ul>
<li>Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%</li>
<li>APG808 demonstrated the potential for durable disease control in asthma with sustained FeNO decrease from baseline of 50% at 12 weeks</li>
<li>APG808's optimized formulation and potential best-in-class pharmacokinetic (PK) profile, combined with robust and sustained FeNO suppression through 12 weeks, support the potential for transformative dosing every 2-months or longer, compared to the current biweekly standard of care</li>
<li>APG808 was well tolerated with a favorable safety profile consistent with the anti-IL-4Rα class</li>
<li>Phase 1b proof-of-concept data validates Apogee's approach to designing potentially best-in-class biologics and builds on Apogee's track record of execution</li>
</ul>

APGE

Apogee Therapeutics Released Interim Data From Its Phase 1b Trial Of APG808, A Novel Half-life Extended IL-4Rα Antibody, In Patients With Mild-to-moderate Asthma

Vertical Aerospace ("Vertical") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) today announced it is developing a hybrid-electric vertical-take-off-and landing (VTOL) variant of its VX4 aircraft, expanding range and payload capabilities to unlock new market opportunities within the already sizable $1TR1 total addressable urban air mobility market.
&nbsp;
&nbsp;
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre
Vertical's hybrid-electric strategy builds on its all-electric VX4 and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvertical-aerospace.com%2Fwp-content%2Fuploads%2F2024%2F11%2FVertical-Aerospace-Launches-Flightpath-2030-a-strategy-to-pioneer-electric-aviation.pdf&amp;esheet=54252992&amp;newsitemid=20250512888129&amp;lan=en-US&amp;anchor=Flightpath+2030+strategy&amp;index=1&amp;md5=4ff01c56d06d0d49334fe4ce9c9c11f4">Flightpath 2030 strategy</a>, enabling new potential applications in defence, logistics and commercial sectors including air ambulance services, which require longer range and higher payload than current eVTOL platforms can deliver.
Vertical's second-generation hybrid-propulsion system, which has been in development for 18 months at the Vertical Energy Centre, will be retrofitted into one of the company's VX4 full scale prototypes and is expected to commence flight testing in Q2 2026.

EVTL

Vertical Aerospace Unveils Hybrid Air Taxi to Boost Range, Targeting $1T Urban Air Mobility Market

<ul>
<li>Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling</li>
<li>First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026</li>
<li>APG279 on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026</li>
<li>Positive interim Phase 1b readout of APG808 in patients with mild-to-moderate asthma demonstrated rapid, robust and sustained suppression of FeNO, a biomarker of Type 2 inflammation that is associated with exacerbations in asthma</li>
</ul>

Guidance

Apogee Therapeutics Cash, Cash Equivalents And Marketable Securities Were $681.4M As Of March 31, 2025 That Supports Runway Into Q1 2028

Allot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $23.20 million which beat the analyst consensus estimate of $20.20 million by 14.85 percent. This is a 5.98 percent increase over sales of $21.89 million the same period last year.

Earnings Beats

ALLT

Allot Q1 Adj. EPS $0.02 Beats $(0.05) Estimate, Sales $23.20M Beat $20.20M Estimate

Earnings Misses

ORLA

Orla Mining Q1 Adj. EPS $0.12 Beats $0.10 Estimate, Sales $140.67M Miss $163.19M Estimate

Keybanc analyst Steve Barger upgrades Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) from Sector Weight to Overweight and announces $110 price target.

Upgrades

Price Target

Analyst Ratings

Keybanc Upgrades Federal Signal to Overweight, Announces $110 Price Target

Rumors

Tech

AAPL

The Wall Street Journal Reported Apple Is Weighing Fall iPhone Price Increases; Won't Attribute Hikes to Tariffs

OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) reported quarterly sales of $45.70 million which beat the analyst consensus estimate of $42.28 million by 8.08 percent. This is a 63.69 percent increase over sales of $27.92 million the same period last year.

OrganiGram Holdings Q2 Sales $45.70M Beat $42.28M Estimate

Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), a company developing electric air taxis for commercial passenger service, today announced it has successfully flown two of its aircraft simultaneously for the first time, marking another important milestone in the Company's flight testing program.
&nbsp;
&nbsp;
Two Joby air taxis (N541JX and N544JX) flying simultaneously in the skies over Marina, CA. Joby Aviation photo
The two-aircraft flight, completed in Marina, CA, on May 9, is a further demonstration of the maturity of Joby's test program, and comes just two weeks after the Company announced it had reached another testing landmark, successfully completing flights with a full transition from vertical to cruise flight, and back again, with a pilot onboard.

JOBY

Joby Aviation Flies Two Air Taxis Together for First Time, Marking Major Leap Toward Commercial Launch

EVEX

Eve Holding Q1 EPS $(0.16) Misses $(0.14) Estimate

GUIDANCE
Rockwell confirms its 2025 annual guidance as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2025 Annual Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">$65.0M to $70.0M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">16% to 18%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">($0.5)M to $0.5M</td>
</tr>
</tbody>
</table>
</figure>

RMTI

Rockwell Medical Affirms FY2025 Sales Guidance of $65.00M-$70.00M vs $67.42M Est

Aurinia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) affirms FY2025 sales outlook from $250.00 million-$260.00 million to $250.00 million-$260.00 million vs $257.87 million estimate.

Comments

Chemours

Actualités

Dernières nouvelles pour Chemours (NYSE:CC) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL